Related references
Note: Only part of the references are listed.Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Niklas Mattsson-Carlgren et al.
EMBO MOLECULAR MEDICINE (2021)
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
Tim West et al.
MOLECULAR NEURODEGENERATION (2021)
Biomarkers for neurodegenerative diseases
Oskar Hansson
NATURE MEDICINE (2021)
Revisiting FDA Approval of Aducanumab
G. Caleb Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
Nicholas C. Cullen et al.
NATURE COMMUNICATIONS (2021)
Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease
Shorena Janelidze et al.
JAMA NEUROLOGY (2021)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study
Frank de Wolfa et al.
BRAIN (2020)
Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline
Petrazzuoli Ferdinando et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Comparing progression biomarkers in clinical trials of early Alzheimer's disease
Nicholas C. Cullen et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward
Michael E. Belloy et al.
NEURON (2019)
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
Clifford R. Jack et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
Sebastian Palmqvist et al.
JAMA NEUROLOGY (2019)
Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
Niklas Mattsson et al.
JAMA NEUROLOGY (2019)
Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
Sebastian Palmqvist et al.
ALZHEIMERS & DEMENTIA (2019)
Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
Ganesh M. Babulal et al.
ALZHEIMERS & DEMENTIA (2019)
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch et al.
ALZHEIMERS & DEMENTIA (2019)
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Ron Brookmeyer et al.
ALZHEIMERS & DEMENTIA (2018)
APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: A review
M. Clare O'Donoghue et al.
CORTEX (2018)
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Akinori Nakamura et al.
NATURE (2018)
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Harald Hampel et al.
NATURE REVIEWS NEUROLOGY (2018)
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Jeffrey Cummings
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Roy M. Anderson et al.
LANCET (2017)
Beta-amyloid and Cortical Thickness Reveal Racial Disparities in Preclinical Alzheimer's Disease
Ian M. McDonough
NEUROIMAGE-CLINICAL (2017)
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Vitaliy Ovod et al.
ALZHEIMERS & DEMENTIA (2017)
Increased amyloidogenic APP processing in APOE ε4-negative individuals with cerebral β-amyloidosis
Niklas Mattsson et al.
NATURE COMMUNICATIONS (2016)
Clinical Impact of Amyloid Positron Emission Tomography-Is It Worth the Cost?
Richard J. Caselli et al.
JAMA NEUROLOGY (2016)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Secondary Prevention Trials in Alzheimer Disease The Challenge of Identifying a Meaningful End Point
Richard J. Kryscio
JAMA NEUROLOGY (2014)
Can we prevent Alzheimer's disease? Secondary prevention trials in Alzheimer's disease
Maria C. Carrillo et al.
ALZHEIMERS & DEMENTIA (2013)
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease
P. J. Visser et al.
NEUROEPIDEMIOLOGY (2008)
Share Paper
